Kura Oncology-backed Caspian advances KO-7246 toward Phase 1 diabetes proof-of-concept study

• Kura Oncology outlined a development plan for KO-7246, an oral menin inhibitor for diabetes, with an investor webcast scheduled for today.
• Preclinical findings were already presented at the EASD meeting, supporting a move toward clinical proof of concept.
• Animal studies showed improved glucose control with signs of restored insulin-producing capacity, including effects that persisted after dosing stopped.
• Human islet testing indicated selective expansion of insulin-producing cells, supporting the therapeutic rationale for diabetes.
• IND-enabling work is underway for a Phase 1 study to assess safety and look for evidence of increased endogenous insulin production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130730PRIMZONEFULLFEED9844315) on October 13, 2026, and is solely responsible for the information contained therein.